IGC Pharma, Inc. (India Globalization Capital, Inc.) — Form 10-Q Summary
Reporting period: Three months ended June 30, 2021, the first quarter of the company’s fiscal 2022. Financial amounts below are in U.S. dollars; “million” and “thousand” are stated for clarity.
Business context and financial performance
The company operates Infrastructure and Life Sciences segments. Life Sciences includes cannabinoid-based drug research and wellness products; Infrastructure includes construction contracts, equipment rental, and commodity sales, primarily in Asia. Management said COVID-19 restrictions continued to disrupt operations, especially in India and Hong Kong.
| Metric | Three months ended June 30, 2021 | Comparable 2020 period |
|---|---|---|
| Revenue | $77,000 | $584,000 |
| Gross profit (margin) | $26,000 (about 34%) | $46,000 (about 8%) |
| Operating loss | $2.194 million | $1.931 million |
| Net loss | $1.788 million | $1.882 million |
| Net cash used in operating activities | $1.851 million | $3.988 million |
| Net cash used in investing activities | $95,000 | $1.136 million |
| Net cash provided by financing activities | $726,000 | $580,000 |
Life Sciences revenue was $62,000, down from $584,000; Infrastructure contributed $15,000, versus none in the prior-year quarter. Research and development expense doubled to $444,000, primarily for the Alzheimer’s clinical trial. Selling, general and administrative expense was approximately $1.776 million, broadly stable year over year. Other income of $443,000 included $430,000 from forgiveness of the company’s Paycheck Protection Program loan. Loss per share was $0.04, compared with $0.05.
Balance sheet, liquidity and capital
- At June 30, cash and cash equivalents were $13.319 million, down $1.229 million from March 31. Working capital was $20.078 million; total assets were $34.444 million and stockholders’ equity was $31.737 million.
- Total liabilities were $2.707 million. Loans totaled approximately $150,000, comprising a $147,000 long-term Economic Injury Disaster Loan and $3,000 current portion. The $430,000 PPP loan was fully forgiven in June.
- Operating lease liabilities were $547,000, including $114,000 current and $433,000 non-current.
- Cash used in operations was $1.851 million for the quarter. The company raised $726,000 net through its at-the-market (ATM) share offering. Management stated that available liquidity was expected to cover working capital, trials, and other needs for the next 12 months, while also saying it would continue seeking financing.
- The ATM agreement permits sales of up to $75 million of common stock. After quarter-end, the company reported approximately $3.4 million of net ATM proceeds through July 23. Shares outstanding were 48.284 million at June 30 and 49.784 million on August 3.
Material changes, outlook and risks
- Revenue declined 87% year over year. Management attributed weak and unpredictable segment results largely to COVID-19 disruption and said it had limited visibility on when revenue would stabilize; it expected Infrastructure revenue to remain reduced during fiscal 2022.
- The company completed the final cohort of the Phase 1 IGC-AD1 Alzheimer’s trial and was compiling safety and tolerability data for submission to the FDA. Further trials, funding, regulatory approval, and evidence of efficacy remain uncertain; management expects R&D costs to rise as trials progress.
- The USPTO issued a patent relating to IGC-AD1 on July 20, 2021, after the reporting date. A patent grant does not establish clinical efficacy or FDA approval.
- A vendor reported theft of inventory valued at approximately $1.74 million. The amount remains recorded within deposits and advances; the vendor filed an insurance claim, and the company said it continues to pursue compensation.
- Shareholder class-action litigation had a preliminary settlement agreement in principle, subject to final documentation and court approval. The company recorded a $200,000 provision and expected a significant portion of settlement costs to be covered by insurance, but the outcome and timing were not assured. Separate litigation involving Apogee and the CEO remained pending; the company denied liability and intended to defend itself.
- Additional risks include clinical-trial failure or delay, regulatory and intellectual-property uncertainty, financing needs and dilution from equity sales, COVID-19 effects, foreign-exchange exposure, and uncertain recovery of claims and advances. Management reported disclosure controls were effective.
Most important facts for investors to verify
- Whether IGC-AD1 trial data support further trials, and the FDA’s response to submitted safety and tolerability information.
- Cash burn, future financing requirements, ATM share sales, and resulting dilution; confirm whether management’s stated 12-month liquidity expectation remains supportable.
- Recoverability and insurance status of the $1.74 million stolen-inventory balance and the $375,000 claim receivable from Cochin International Airport.
- Final terms, court approval, insurance coverage, and total cost of the shareholder settlement, as well as developments in the Apogee litigation.
- Whether revenue recovers from the unusually low quarter and whether Life Sciences products or Infrastructure activity can generate sustainable sales.